Compare BIO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIO | ROIV |
|---|---|---|
| Founded | 1952 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 28.7B |
| IPO Year | 1994 | 2021 |
| Metric | BIO | ROIV |
|---|---|---|
| Price | $379.84 | $36.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $328.33 | $48.08 |
| AVG Volume (30 Days) | 256.6K | ★ 7.3M |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,583,200,000.00 | $8,260,000.00 |
| Revenue This Year | N/A | $530.75 |
| Revenue Next Year | $2.13 | $685.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.65 | N/A |
| 52 Week Low | $236.73 | $15.25 |
| 52 Week High | $396.23 | $42.50 |
| Indicator | BIO | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 54.13 | 44.28 |
| Support Level | $364.41 | $33.15 |
| Resistance Level | $392.81 | $37.59 |
| Average True Range (ATR) | 11.36 | 1.24 |
| MACD | -2.15 | -0.44 |
| Stochastic Oscillator | 76.00 | 14.50 |
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.